Enveric Biosciences to receive anxiety disorder drug patent, shares jump

Enveric Biosciences

18/05/2023 16:29

(Updates)
    ** Shares of biotech firm Enveric Biosciences Inc  ENVB.O 
more than double to $3.46 
        ** Stock top pct. gainer across U.S. stock exchanges
  
    ** Company to receive patent for application involving its
lead drug candidate being developed as a treatment for anxiety
disorder
    ** The soon-to-be-issued patent contains claims pertaining
to the way in which a substance is used or the nature of the
components for a family of novel prodrug derivatives of psilocin
    ** YTD co's stock up 65.8%, including session's gain

 (Reporting by Khushi Mandowara and Pratik Jain in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))